Foundation Medicine, Novartis partner up on companion diagnostics in oncology

Foundation Medicine, Novartis partner up on companion diagnostics in oncology

A company focused on next-generation sequencing-based diagnostics is partnering with a large Swiss drugmaker. Foundation Medicine, based in Cambridge, Massachusetts, said Wednesday that it had formed a collaboration with Novartis. The development and commercialization partnership will involve Novartis using the diagnostics maker’s comprehensive genomic profiling assay, FoundationOne CDx, to […] Click here to view original[…]

Promising Agents Could Alter the Treatment Paradigm in Metastatic TNBC

Promising Agents Could Alter the Treatment Paradigm in Metastatic TNBC

Joyce A. O’Shaughnessy, MD Since triple-negative breast cancer (TNBC) is resistant to multiple therapies, physicians have little flexibility for treatment options. However, anticipation is building for potential alternatives. “Right now, for TNBC, chemotherapy is our only option,” said Joyce A. O’Shaughnessy, MD, co-chair of Breast Cancer Research and the […] Click here to view original[…]

Recent advances push forward the field of molecular oncology

A number of recent advances in molecular oncology are noteworthy for our new regular column, which launched in September. Here is an overview of those developments and their potential impacts. BRCA1 gene variants unraveled — An important advance reported by Findlay and colleagues in Nature involves progress in unraveling […] Click here to view original[…]

FDA approves Regeneron, Sanofi skin cancer immuno-oncology drug

FDA approves Regeneron, Sanofi skin cancer immuno-oncology drug

Regeneron headquarters in Tarrytown. Tarrytown-based Regeneron Pharmaceuticals Inc. and French pharma company Sanofi have received U.S. Food and Drug Administration approval for an immuno-oncology drug to treat skin cancer in patients who do not respond to surgery or radiation. Regeneron announced jointly with Paris-based Sanofi that the drug Libtayo […] Click here to view original[…]

Bispecific Molecules in Oncology: Analytical Tool

Bispecific Molecules in Oncology: Analytical Tool

NEW YORK, Oct. 4, 2018 /PRNewswire/ — Bispecific molecules carry huge treatment potential within cancer immunotherapy. In broad strokes this therapeutic category can be divided into three classes: (I) cytotoxic effector cell redirectors/CTL response; (II) tumor-targeted immunomodulators; and (II) dual immunomodulators. Read the full report: https://www.reportlinker.com/p05576157 Bispecific Molecules in […] Click here to view original[…]

New Treatments Options a 'Game-Changer' in Esophagogastric Ca

New Treatments Options a ‘Game-Changer’ in Esophagogastric Cancer

For the first time, a third-line treatment in heavily pretreated Western patients with chemotherapy-refractory esophagogastric cancer has demonstrated clinically meaningful antitumor activity, durable responses, encouraging long-term overall survival (OS), and a manageable safety profile, researchers said. Results from 160 patients in the ongoing CheckMate-032 study showed an objective response […] Click here to view original[…]

Real Costs Up to 8% Higher for Some Cancers in Oncology Care Model

Real Costs Up to 8% Higher for Some Cancers in Oncology Care Model

Source: Thinkstock The Oncology Care Model (OCM) is a voluntary bundled payments initiative that aims to decrease costs and improve care quality for cancer care. The five-year model currently has 179 oncology practices and 13 payers participating across the country. The OCM includes bundled payment tracks for 21 cancer […] Click here to view original[…]

FDA Recommends Use of Placebo Only in Certain Oncology Trials

FDA Grants Priority Review to Keytruda as First-line Therapy for Advanced NSCLC

The U.S. Food and Drug Administration (FDA) has agreed to review Merck ‘s application seeking the extension of Keytruda ( pembrolizumab ) as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC). The supplemental Biologics License Application (sBLA) was granted priority review and a decision is expected […] Click here to view original[…]

Training, retaining APPs ‘of paramount importance’ to oncology workforce

Editor’s note: HemOnc Today ’s regular columns for advanced practice providers (APPs) tackle common issues APPs face, discuss day-to-day practice and regulatory concerns, and share research advances. To contribute to this column, contact Alexandra Todak at stodak@healio.com . Nurse practitioners and physician assistants are an increasing and integral part […] Click here to view original[…]